

DAFTAR PUSTAKA

- Abbas Mohaned, G.M., A.A. (2018), *Abbas M, Gissmala M, Axillary Lymph Node Dissection for Breast Cancer: Efficacy and Complication in Developing Countries*.
- Akshata Desai, K.A. (2012), “Triple Negative Breast Cancer – An Overview”, *Hereditary Genetics*, OMICS Publishing Group, doi: 10.4172/2161-1041.s2-001.
- Aleskandarany, M.A., Sonbul, S.N., Mukherjee, A. and Rakha, E.A. (2015), “Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer”, *Pathobiology*, S. Karger AG, 23 September, doi: 10.1159/000433583.
- Alitalo, K. and Carmeliet, P. (2002), *R E V I E W Molecular Mechanisms of Lymphangiogenesis in Health and Disease*.
- Almansour, N.M. (2022), “Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence”, *Frontiers in Molecular Biosciences*, Frontiers Media S.A., 25 January, doi: 10.3389/fmolb.2022.836417.
- Behring, M., Bajpai, P., Afaq, F., Elkholy, A., Kim, H.-G., Al Diffalha, S., Shrestha, S., *et al.* (2022), “Age-Dependent Heterogeneity of Lymph Node Metastases and Survival Identified by Analysis of a National Breast Cancer Registry”, *Journal of Pharmacy and Pharmacology Research*, Vol. 06 No. 03, pp. 147–157, doi: 10.26502/fjppr.060.
- Breast Cancer Research Foundation. (2025), “Breast cancer grades and what they mean”, *Breast Cancer Research Foundation*.
- Buyuk, B., Jin, S. and Ye, K. (2022), “Epithelial-to-Mesenchymal Transition Signaling Pathways Responsible for Breast Cancer Metastasis”, *Cellular and Molecular Bioengineering*, Springer, 1 February, doi: 10.1007/s12195-021-00694-9.
- Chen, W., Wang, C., Fu, F., Yang, B., Chen, C. and Sun, Y. (2020), “A model to predict the risk of lymph node metastasis in breast cancer based on clinicopathological characteristics”, *Cancer Management and Research*, Vol. 12, pp. 10439–10447, doi: 10.2147/CMAR.S272420.

- Chintapally, N., Englander, K., Gallagher, J., Elleson, K., Sun, W., Whiting, J., Laronga, C., *et al.* (2023), “Tumor Characteristics Associated with Axillary Nodal Positivity in Triple Negative Breast Cancer”, *Diseases*, Vol. 11 No. 3, pp. 1–12, doi: 10.3390/diseases11030118.
- Cui, X., Zhu, H. and Huang, J. (2020), “Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer”, *Frontiers in Oncology*, Vol. 10 No. December, pp. 1–7, doi: 10.3389/fonc.2020.608334.
- Dogan, N.U., Dogan, S., Favero, G., Köhler, C. and Dursun, P. (2019), “The Basics of Sentinel Lymph Node Biopsy: Anatomical and Pathophysiological Considerations and Clinical Aspects”, *Journal of Oncology*, Hindawi Limited, Vol. 2019, doi: 10.1155/2019/3415630.
- Dogra, A.K., Prakash, A., Gupta, S. and Gupta, M. (2025), “Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review”, *European Journal of Breast Health*, Vol. 21 No. 2, pp. 101–114, doi: 10.4274/ejbh.galenos.2025.2024-10-2.
- Egeblad, M. and Werb, Z. (2002), “New functions for the matrix metalloproteinases in cancer progression”, *Nature Reviews Cancer*, European Association for Cardio-Thoracic Surgery, doi: 10.1038/nrc745.
- Ernard, B., Isher, F., Nderson, T.A., Ohn, J., Ryant, B., Argolese, I.G.M., Eutsch, E.D., *et al.* (2002), *TWENTY-YEAR FOLLOW-UP OF A RANDOMIZED TRIAL COMPARING TOTAL MASTECTOMY, LUMPECTOMY, AND LUMPECTOMY PLUS IRRADIATION FOR THE TREATMENT OF INVASIVE BREAST CANCER A BSTRACT*, *N Engl J Med*, Vol. 347.
- Filić, V., Marinović, M., Faix, J. and Weber, I. (2012), “A dual role for Rac1 GTPases in the regulation of cell motility”, *Journal of Cell Science*, Vol. 125 No. 2, pp. 387–398, doi: 10.1242/jcs.089680.
- Fu, X.D. (2017), “Both sides of the same coin: Rac1 splicing regulating by EGF signaling”, *Cell Research*, Nature Publishing Group, Vol. 27 No. 4, pp. 455–456, doi: 10.1038/cr.2017.19.
- Fujimoto, N. and Dieterich, L.C. (2021), “Mechanisms and clinical significance of tumor lymphatic invasion”, *Cells*, Vol. 10 No. 10, doi: 10.3390/cells10102585.
- Guo, Y., Arciero, C.A., Jiang, R., Behera, M., Peng, L. and Li, X. (2020), “Different Breast Cancer Subtypes Show Different Metastatic Patterns: A

Study from A Large Public Database”, *Asian Pacific Journal of Cancer Prevention*, Asian Pacific Organization for Cancer Prevention, Vol. 21 No. 12, pp. 3587–3593, doi: 10.31557/APJCP.2020.21.12.3587.

Handayani, P., Jasrin, T.A. and Widyaputra, S. (2016), “<p>Limfangiogenesis sebagai jalur alternatif metastasis kanker</p><p>Lymphangiogenesis as an alternative pathway for cancer metastasis</p>”, *Jurnal Kedokteran Gigi Universitas Padjadjaran*, Universitas Padjadjaran, Vol. 28 No. 2, doi: 10.24198/jkg.v28i2.18707.

He, Z.Y., Wu, S.G., Yang, Q., Sun, J.Y., Li, F.Y., Lin, Q. and Lin, H.X. (2015), “Breast cancer subtype is associated with axillary lymph node metastasis”, *Medicine (United States)*, Lippincott Williams and Wilkins, Vol. 94 No. 48, doi: 10.1097/MD.0000000000002213.

Hemida, A.S., Abdelaziz, R.A., Abd El-Wahed, M.M., Asaad, N.Y., Serag El-Dien, M.M. and Elshahat Ali, H.A. (2024), “Significance of RCC2, Rac1 and p53 Expression in Breast Infiltrating Ductal Carcinoma; An Immunohistochemical Study”, *Iranian Journal of Pathology*, Vol. 19 No. 2, pp. 177–192, doi: 10.30699/ijp.2024.2014367.3198.

Heriady, Y., Achmad, D., Hernowo, B.S., Faried, A., Ismono, D. and Hilmanto, D. (2019), “Expression of the RAC1, RHOA and CXCR4 proteins and their interaction as risk factors for infiltration to the nipple areola complex in operable breast carcinoma”, *Breast Cancer*, Springer Tokyo, Vol. 26 No. 2, pp. 172–179, doi: 10.1007/s12282-018-0907-z.

Humphries, B., Wang, Z. and Yang, C. (2020), “Rho GTPases: Big Players in Breast Cancer Initiation, Metastasis and Therapeutic Responses”, *Cells*, NLM (Medline), 25 September, doi: 10.3390/cells9102167.

Ji, H., Cao, R., Yang, Y., Zhang, Y., Iwamoto, H., Lim, S., Nakamura, M., *et al.* (2014), “TNFR1 mediates TNF- α -induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling”, *Nature Communications*, Nature Publishing Group, Vol. 5, doi: 10.1038/ncomms5944.

Ji, H., Hu, C., Yang, X., Liu, Y., Ji, G., Ge, S., Wang, X., *et al.* (2023), “Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions”, *Signal Transduction and Targeted Therapy*, Springer Nature, 1 December, doi: 10.1038/s41392-023-01576-4.

- Joyce, J.A. and Pollard, J.W. (2009), “Microenvironmental regulation of metastasis”, *Nature Reviews Cancer*, April, doi: 10.1038/nrc2618.
- Kim, H.J., Kim, S., Freedman, R.A. and Partridge, A.H. (2022), “The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis”, *Breast*, The Authors, Vol. 61, pp. 77–83, doi: 10.1016/j.breast.2021.12.006.
- Kuhn, E., Gambini, D., Despini, L., Asnaghi, D., Runza, L. and Ferrero, S. (2023), “Updates on Lymphovascular Invasion in Breast Cancer”, *Biomedicines*, Vol. 11 No. 3, pp. 1–13, doi: 10.3390/biomedicines11030968.
- Kumar, V., Abbas, A.K., Aster, J.C. and Perkins, J.A. (n.d.). *Robbins and Cotran Pathologic Basis of Disease*.
- Labrousse, A.M., Zappaterra, M.D., Rube, D.A., van der Blik, A.M., Vater, C.A., Raymond, C.K., Ekena, K., *et al.* (1998), 42. *J. Nunnari, Unpublished Data, Annu. Rev. Plant Physiol. Plant Mol. Biol*, Vol. 143, H. Hashimoto.
- Lee, S.J., Go, J., Ahn, B.S., Ahn, J.H., Kim, J.Y., Park, H.S., Kim, S. Il, *et al.* (2023a), “Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes”, *Frontiers in Oncology*, Frontiers Media SA, Vol. 13, doi: 10.3389/fonc.2023.1269971.
- Lee, S.J., Go, J., Ahn, B.S., Ahn, J.H., Kim, J.Y., Park, H.S., Kim, S. Il, *et al.* (2023b), “Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes”, *Frontiers in Oncology*, Vol. 13 No. November, doi: 10.3389/fonc.2023.1269971.
- Li, Q., Qin, T., Bi, Z., Hong, H., Ding, L., Chen, J., Wu, W., *et al.* (2020), “Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer”, *Nature Communications*, Springer US, Vol. 11 No. 1, doi: 10.1038/s41467-020-15308-7.
- Lian, J., Yue, Y., Yu, W. and Zhang, Y. (2020), “Immunosenescence: a key player in cancer development”, *Journal of Hematology and Oncology*, BioMed Central, Vol. 13 No. 1, pp. 1–18, doi: 10.1186/s13045-020-00986-z.
- Liang, J., Oyang, L., Rao, S., Han, Y., Luo, X., Yi, P., Lin, J., *et al.* (2021), “Rac1, A Potential Target for Tumor Therapy”, *Frontiers in Oncology*, Vol. 11 No. May, pp. 1–17, doi: 10.3389/fonc.2021.674426.

- Liu, B., Xiong, J., Liu, G., Wu, J., Wen, L., Zhang, Q. and Zhang, C. (2017), “High expression of *rac1* is correlated with partial reversed cell polarity and poor prognosis in invasive ductal carcinoma of the breast”, *Tumor Biology*, SAGE Publications Ltd, Vol. 39 No. 7, pp. 1–8, doi: 10.1177/1010428317710908.
- Lozano, E., Betson, M. and Braga, V.M.M. (2003), “Tumor progression: Small GTPases and loss of cell-cell adhesion”, *BioEssays*, 1 May, doi: 10.1002/bies.10262.
- Luo, M., Lin, X., Hao, D., Shen, K.W., Wu, W., Wang, L., Ruan, S., *et al.* (2023), “Incidence and risk factors of lymph node metastasis in breast cancer patients without preoperative chemoradiotherapy and neoadjuvant therapy: analysis of SEER data”, *Gland Surgery*, Vol. 12 No. 11, pp. 1508–1524, doi: 10.21037/gs-23-258.
- Ma, N., Xu, E., Luo, Q. and Song, G. (2023), “Rac1: A Regulator of Cell Migration and a Potential Target for Cancer Therapy”, *Molecules*, MDPI, 1 April, doi: 10.3390/molecules28072976.
- Makki, J. (2015), “Diversity of breast carcinoma: Histological subtypes and clinical relevance”, *Clinical Medicine Insights: Pathology*, Libertas Academica Ltd., Vol. 8 No. 1, pp. 23–31, doi: 10.4137/CPath.s31563.
- Manfioletti, G. and Fedele, M. (2023), “Epithelial–Mesenchymal Transition (EMT)”, *International Journal of Molecular Sciences*, Multidisciplinary Digital Publishing Institute (MDPI), 1 July, doi: 10.3390/ijms241411386.
- Marconi, G.D., Fonticoli, L., Rajan, T.S., Pierdomenico, S.D., Trubiani, O., Pizzicannella, J. and Diomede, F. (2021), “Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis”, Vol. 10, doi: 10.3390/cells.
- Marei, H. and Malliri, A. (2017), “Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms”, *Small GTPases*, Taylor and Francis Inc., 3 July, doi: 10.1080/21541248.2016.1211398.
- Masuda, H., Harano, K., Miura, S., Wang, Y., Hirota, Y., Harada, O., Mohit, ;, *et al.* (2022), “Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy”, doi: 10.1200/PO.20.

Mayrovitz, H.N. (n.d.). *Breast Cancer*.

Min, S.K., Lee, S.K., Woo, J., Jung, S.M., Ryu, J.M., Yu, J., Lee, J.E., *et al.* (2021), “Relation between tumor size and lymph node metastasis according to subtypes of breast cancer”, *Journal of Breast Cancer*, Vol. 24 No. 1, pp. 75–84, doi: 10.4048/jbc.2021.24.e4.

Mohapatra, M. (2023), “Clinicopathological and prognostic characteristic features of triple negative and nontriple negative breast cancer at a tertiary care hospital”, *Journal of Cancer Research and Therapeutics*, Wolters Kluwer Medknow Publications, Vol. 19 No. 5, pp. 1186–1193, doi: 10.4103/jcrt.jcrt_1222_21.

Moo, T.A., Sanford, R., Dang, C. and Morrow, M. (2018), “Overview of Breast Cancer Therapy”, *PET Clinics*, W.B. Saunders, 1 July, doi: 10.1016/j.cpet.2018.02.006.

National Cancer Institute. (2022), “Tumor Grade”, *National Cancer Institute*.

Naxerova, K. (2020), “Defining the role of lymph node metastasis in systemic breast cancer evolution”, *EBioMedicine*, Elsevier B.V., 1 July, doi: 10.1016/j.ebiom.2020.102852.

Nussinov, R., Yavuz, B.R. and Jang, H. (2025), “Molecular principles underlying aggressive cancers”, *Signal Transduction and Targeted Therapy*, Springer US, Vol. 10 No. 1, doi: 10.1038/s41392-025-02129-7.

Rahmawati, Y., Setyawati, Y., Widodo, I., Ghozali, A. and Purnomosari, D. (2018), “Molecular subtypes of Indonesian breast carcinomas - Lack of association with patient age and tumor size”, *Asian Pacific Journal of Cancer Prevention*, Asian Pacific Organization for Cancer Prevention, Vol. 19 No. 1, pp. 161–166, doi: 10.22034/APJCP.2018.19.1.161.

Ren, W., Liang, H., Sun, J., Cheng, Z., Liu, W., Wu, Y., Shi, Y., *et al.* (2024), “TNFAIP2 promotes HIF1 α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis”, *Cell Death and Disease*, Springer US, Vol. 15 No. 11, doi: 10.1038/s41419-024-07223-2.

Ridley, A.J. (2013), “RhoA, RhoB and RhoC have different roles in cancer cell migration”, *Journal of Microscopy*, Vol. 251 No. 3, pp. 242–249, doi: 10.1111/jmi.12025.

Rozenchan, P.B., Pasini, F.S., Roela, R.A., Katayama, M.L.H., Mundim, F.G.L., Brentani, H., Lyra, E.C., *et al.* (2015), “Specific upregulation of RHOA and

RAC1 in cancer-associated fibroblasts found at primary tumor and lymph node metastatic sites in breast cancer”, *Tumor Biology*, Springer Science and Business Media B.V., Vol. 36 No. 12, pp. 9589–9597, doi: 10.1007/s13277-015-3727-1.

Ryu, Y.J., Kang, S.J., Cho, J.S., Yoon, J.H. and Park, M.H. (2018), “Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy”, *Medicine (United States)*, Lippincott Williams and Wilkins, Vol. 97 No. 30, doi: 10.1097/MD.00000000000011647.

Sandoughdaran, S., Malekzadeh, M. and Akbari, M.E. (2018), “Frequency and predictors of axillary lymph node metastases in Iranian women with early breast cancer”, *Asian Pacific Journal of Cancer Prevention*, Asian Pacific Organization for Cancer Prevention, Vol. 19 No. 6, pp. 1617–1620, doi: 10.22034/APJCP.2018.19.6.1617.

Sauzeau, V., Beignet, J. and Bailly, C. (2022), “Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder”, *Biomedicines*, MDPI, 1 June, doi: 10.3390/biomedicines10061357.

Schnelzer, A., Prechtel, D., Knaus, U., Dehne, K., Gerhard, M., Graef, H., Harbeck, N., *et al.* (n.d.). *Rac1 in Human Breast Cancer: Overexpression, Mutation Analysis, and Characterization of a New Isoform, Rac1b*.

Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023), “Cancer statistics, 2023”, *CA: A Cancer Journal for Clinicians*, Wiley, Vol. 73 No. 1, pp. 17–48, doi: 10.3322/caac.21763.

S.K Lwanga, S.L. (n.d.). “Sample Size Determination in Health Studies . WHO”, 1991.

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021), “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”, *CA: A Cancer Journal for Clinicians*, Wiley, Vol. 71 No. 3, pp. 209–249, doi: 10.3322/caac.21660.

Svitkina, T. (2018), “The actin cytoskeleton and actin-based motility”, *Cold Spring Harbor Perspectives in Biology*, Cold Spring Harbor Laboratory Press, Vol. 10 No. 1, doi: 10.1101/cshperspect.a018267.

- Tan, S., Yi, P., Wang, H., Xia, L., Han, Y., Wang, H., Zeng, B., *et al.* (2020), “RAC1 Involves in the Radioresistance by Mediating Epithelial-Mesenchymal Transition in Lung Cancer”, *Frontiers in Oncology*, Vol. 10 No. April, pp. 1–12, doi: 10.3389/fonc.2020.00649.
- Tang, X., Feng, Y., Zhao, W., Liu, R. and Chen, N. (2024), “Prediction of non-sentinel lymph node metastases in T1-2 sentinel lymph node-positive breast cancer patients undergoing mastectomy following neoadjuvant therapy”, *World Journal of Surgical Oncology*, Vol. 22 No. 1, p. 258, doi: 10.1186/s12957-024-03537-9.
- Tečić Vuger, A., Šeparović, R., Vazdar, L., Pavlović, M., Lepetić, P., Šitić, S., Bajić, Ž., *et al.* (2020), “CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INStitution RETROSPECTIVE COHORT STUDY”, *Acta Clinica Croatica*, NLM (Medline), Vol. 59 No. 1, pp. 97–108, doi: 10.20471/acc.2020.59.01.12.
- Tseliou, M., Al-Qahtani, A., Alarifi, S., Alkahtani, S.H., Stournaras, C. and Sourvinos, G. (2016), “The Role of RhoA, RhoB and RhoC GTPases in Cell Morphology, Proliferation and Migration in Human Cytomegalovirus (HCMV) Infected Glioblastoma Cells”, *Cellular Physiology and Biochemistry*, S. Karger AG, Vol. 38 No. 1, pp. 94–109, doi: 10.1159/000438612.
- Wei, C., Deng, Y., Wei, S., Huang, Z., Xie, Y., Xu, J., Dong, L., *et al.* (2023), “Lymphovascular invasion is a significant risk factor for non-sentinel nodal metastasis in breast cancer patients with sentinel lymph node (SLN)-positive breast cancer: a cross-sectional study”, *World Journal of Surgical Oncology*, BioMed Central, Vol. 21 No. 1, pp. 1–8, doi: 10.1186/s12957-023-03273-6.
- Wertheimer, E., Gutierrez-Uzquiza, A., Rosembli, C., Lopez-Haber, C., Sosa, M.S. and Kazanietz, M.G. (2012), “Rac signaling in breast cancer: A tale of GEFs and GAPs”, *Cellular Signalling*, February, doi: 10.1016/j.cellsig.2011.08.011.
- WHO. (2022), “GLOBOCAN”, available at: https://gco.iarc.fr/today/en/dataviz/pie?mode=cancer&group_populations=1&sexes=2 (accessed 28 July 2024).

- Won, K.A. and Spruck, C. (2020), “Triple-negative breast cancer therapy: Current and future perspectives”, *International Journal of Oncology*, Spandidos Publications, Vol. 57 No. 6, pp. 1245–1261, doi: 10.3892/ijo.2020.5135.
- Xiao, Y., Ma, D., Yang, Y.S., Yang, F., Ding, J.H., Gong, Y., Jiang, L., *et al.* (2022), “Comprehensive metabolomics expands precision medicine for triple-negative breast cancer”, *Cell Research*, Springer Nature, Vol. 32 No. 5, pp. 477–490, doi: 10.1038/s41422-022-00614-0.
- Yamazaki, D., Kurisu, S. and Takenawa, T. (2005), “Regulation of cancer cell motility through actin reorganization”, *Cancer Science*, July, doi: 10.1111/j.1349-7006.2005.00062.x.
- Zhang, Y., Li, J., Fan, Y., Li, X., Qiu, J., Zhu, M. and Li, H. (2019), “Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients”, *Medicine (United States)*, Lippincott Williams and Wilkins, Vol. 98 No. 40, doi: 10.1097/MD.00000000000017481.
- Zhang, Y., Wang, H., Zhao, H., He, X., Wang, Y. and Wang, H. (2024), “Prognostic significance and value of further classification of lymphovascular invasion in invasive breast cancer: a retrospective observational study”, *Breast Cancer Research and Treatment*, Springer US, Vol. 206 No. 2, pp. 397–410, doi: 10.1007/s10549-024-07318-6.
- Zhu, H. and Doğan, B.E. (2021), “American Joint Committee on Cancer’s Staging System for Breast Cancer, Eighth Edition: Summary for Clinicians”, *European Journal of Breast Health*, Galenos Publishing House, 1 July, doi: 10.4274/ejbh.galenos.2021.2021-4-3.